Red Door Community Raises More Than $300,000 at Their Annual Luncheon Celebrating Women Working and Living With Cancer
Free cancer support programs get a boost, and Red Door Community member announces a run NEW YORK, May 17, 2024 /PRNewswire/ -- On Wednesday, May 15, Red Door Community hosted their annual Celebrating
Boundless Bio Inc. Shifts Corporate Updates to IR Website
Boundless Bio, Inc. Q1 Loss Climbs
Boundless Bio | 10-Q: Quarterly report
Express News | Boundless Bio Inc: First Patient Dosed in Phase 1/2 Starmap Clinical Trial of Bbi-825 in Patients With Tumors With Resistance Gene Amplifications
Express News | Boundless: Bbi-355 Phase 1/2 Potentiate Clinical Trial Ongoing;Initiated Therapy Combinations for Tumors With Egfr/Fgfr Oncogene Amplifications
Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD
Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Express News | Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...
Boundless Bio Initiated at Outperform by Leerink Partners
Boundless Bio Initiated at Outperform by Leerink Partners
Express News | Leerink Partners Initiates Coverage On Boundless Bio With Outperform Rating, Announces Price Target of $25
Express News | Guggenheim Initiates Coverage On Boundless Bio With Buy Rating, Announces Price Target of $24
Analysts' Opinions Are Mixed on These NA Stocks: Boundless Bio Inc. (BOLD) and Solventum Corporation (SOLV)
Express News | Boundless Bio Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $25
Boundless Bio Initiated at Overweight by Piper Sandler
Boundless Bio Initiated at Overweight by Piper Sandler
Boundless Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 50.49% Piper Sandler → $20 Initiates Coverage On → Overweight 12/09/2019 — Evercore ISI Group
Express News | Boundless Bio Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $20: Piper Sandler Initiates Coverage With Overweight Rating; Price Target $20
Express News | Boundless Bio Doses First Patient In Phase 1/2 Clinical Trial Of BBI-825 In Cancer Patients With Resistance Gene Amplifications
No Data